Rosalind Advisors
Latest statistics and disclosures from Rosalind Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DCTH, XERS, FENC, SVRA, PCVX, and represent 40.82% of Rosalind Advisors's stock portfolio.
- Added to shares of these 10 stocks: PCVX (+$17M), VOR (+$13M), CLDX (+$11M), BCRX (+$8.8M), XERS (+$6.5M), AVIR (+$6.3M), EYPT, XFOR, OVID, DFTX.
- Started 12 new stock positions in VOR, AVIR, Viridian Therapeutics, AQST, LPCN, DFTX, OVID, AVTX, ANNX, PCVX. CLDX, BCRX.
- Reduced shares in these 10 stocks: REPL (-$14M), ATYR (-$14M), CGON (-$14M), CYTK (-$12M), MNMD (-$10M), OCUL, AVBP, VRDN, Spdr S&p 500 Etf Tr option, Anavex Life Sciences Corp put.
- Sold out of its positions in ATYR, Anavex Life Sciences Corp put, AVBP, CYTK, GUTS, Ishares Tr Index option, MNMD, OCUL, REPL, Replimune Group. Rezolute, Spdr S&p Oil & Gas Exp & Pr put, TRVI, Verastem, Viking Therapeutics Inc call, Vistagen Therapeutics.
- Rosalind Advisors was a net seller of stock by $-7.6M.
- Rosalind Advisors has $249M in assets under management (AUM), dropping by -12.53%.
- Central Index Key (CIK): 0001622627
Tip: Access up to 7 years of quarterly data
Positions held by Rosalind Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rosalind Advisors
Rosalind Advisors holds 38 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Delcath Systems Com New (DCTH) | 12.3 | $31M | 3.3M | 9.28 |
|
|
| Xeris Pharmaceuticals (XERS) | 7.5 | $19M | +53% | 3.2M | 5.80 |
|
| Fennec Pharmaceuticals (FENC) | 7.2 | $18M | +11% | 2.9M | 6.15 |
|
| Savara (SVRA) | 7.0 | $18M | -5% | 3.2M | 5.46 |
|
| Vaxcyte (PCVX) | 6.8 | $17M | NEW | 290k | 58.11 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 5.4 | $13M | +50% | 1.0M | 12.89 |
|
| X4 Pharmaceuticals Com New (XFOR) | 5.3 | $13M | +23% | 3.2M | 4.13 |
|
| Vor Biopharma Com New (VOR) | 5.0 | $13M | NEW | 700k | 17.84 |
|
| Mediwound Shs New (MDWD) | 4.8 | $12M | 749k | 16.11 |
|
|
| Verastem Com New (VSTM) | 4.6 | $11M | +19% | 2.1M | 5.30 |
|
| Celldex Therapeutics Com New (CLDX) | 4.2 | $11M | NEW | 330k | 31.72 |
|
| BioCryst Pharmaceuticals (BCRX) | 3.5 | $8.8M | NEW | 923k | 9.52 |
|
| Cybin Com New (HELP) | 3.0 | $7.4M | -7% | 1.5M | 4.80 |
|
| Cg Oncology (CGON) | 2.7 | $6.8M | -66% | 100k | 67.68 |
|
| Inspiremd (NSPR) | 2.6 | $6.4M | 3.9M | 1.63 |
|
|
| Atea Pharmaceuticals (AVIR) | 2.5 | $6.3M | NEW | 1.2M | 5.38 |
|
| Profound Medical Corp Com New (PROF) | 2.2 | $5.4M | -22% | 828k | 6.48 |
|
| Miragen Therapeutics (VRDN) | 2.0 | $4.9M | -44% | 250k | 19.56 |
|
| Replimune Group Call Call Option | 1.1 | $2.7M | +452% | 1.3M | 2.15 |
|
| Polypid (PYPD) | 1.1 | $2.6M | -14% | 598k | 4.38 |
|
| Myomo Com New (MYO) | 1.0 | $2.6M | 3.8M | 0.68 |
|
|
| Talphera Com New (TLPH) | 1.0 | $2.5M | -6% | 3.4M | 0.75 |
|
| Ovid Therapeutics (OVID) | 1.0 | $2.5M | NEW | 1.1M | 2.22 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.9 | $2.4M | NEW | 125k | 18.90 |
|
| Onkure Therapeutics Com Cl A (OKUR) | 0.7 | $1.8M | -39% | 444k | 4.14 |
|
| Lipocine Com New (LPCN) | 0.7 | $1.8M | NEW | 222k | 7.99 |
|
| Neuraxis (NRXS) | 0.7 | $1.7M | 286k | 5.92 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.4 | $1.1M | NEW | 75k | 14.93 |
|
| Annexon (ANNX) | 0.4 | $1.1M | NEW | 200k | 5.54 |
|
| Invesco Qqq Tr Put Put Option | 0.4 | $1.1M | -44% | 250k | 4.21 |
|
| Aquestive Therapeutics (AQST) | 0.4 | $1.0M | NEW | 250k | 4.15 |
|
| Spdr S&p 500 Etf Tr Put Put Option | 0.4 | $959k | -75% | 125k | 7.67 |
|
| Biofrontera Com New (BFRI) | 0.4 | $942k | +2% | 1.2M | 0.81 |
|
| Kura Oncology (KURA) | 0.3 | $813k | 100k | 8.13 |
|
|
| Regentis Biomaterials Ordinary Shares (RGNT) | 0.3 | $768k | 252k | 3.06 |
|
|
| Viridian Therapeutics Put Put Option | 0.0 | $53k | NEW | 264k | 0.20 |
|
| Uniqure Nv Call Call Option | 0.0 | $0 | +195% | 296k | 0.00 |
|
| Arrivent Biopharma Call Call Option | 0.0 | $0 | 109k | 0.00 |
|
Past Filings by Rosalind Advisors
SEC 13F filings are viewable for Rosalind Advisors going back to 2023
- Rosalind Advisors 2026 Q1 filed May 14, 2026
- Rosalind Advisors 2025 Q4 filed Feb. 12, 2026
- Rosalind Advisors 2025 Q3 filed Nov. 13, 2025
- Rosalind Advisors 2025 Q2 filed Aug. 14, 2025
- Rosalind Advisors 2025 Q1 filed May 14, 2025
- Rosalind Advisors 2024 Q4 restated filed Feb. 14, 2025
- Rosalind Advisors 2024 Q3 filed Oct. 30, 2024
- Rosalind Advisors 2024 Q2 filed July 12, 2024
- Rosalind Advisors 2024 Q1 filed April 25, 2024
- Rosalind Advisors 2023 Q4 filed Feb. 14, 2024